erlotinib hydrochloride

Phase 3

UUniversity of Texas Southwestern Medical Center

erlotinib hydrochloride is one of 9 therapeutic programs targeting Recurrent Lung Non-Small Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Recurrent Lung Non-Small Cell CarcinomaActive, not recruiting

Cirrhosis, LiverNot yet recruiting

Lung Non-Squamous Non-Small Cell CarcinomaActive, not recruiting

Recurrent Lung Non-Small Cell CarcinomaPhase 2

Active, not recruiting

Cirrhosis, LiverPhase 2

Not yet recruiting

Lung Non-Squamous Non-Small Cell CarcinomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Recurrent Lung Non-Small Cell Carcinoma

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 3

1 2

Taxol

Teva

Phase 3

1 3

Paraplatin

AAvyxa

Phase 3

1 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 5

Vepesid

AAvyxa

Phase 3

1 6

Alimta

GGynecologic Oncology Group

Phase 3

1 7

Cometriq

EExelixis

Phase 2

1 8

erlotinib hydrochloride

UUniversity of Texas Southwestern Medical Center

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Lung Non-Squamous Non-Small Cell Carcinoma

NCT02193282

Phase 2Active, not recruiting

Recurrent Lung Non-Small Cell Carcinoma

NCT01708954

Q3 2030

Phase 2Not yet recruiting

Cirrhosis, Liver

NCT04172779

Clinical

Trials by Indication[1]

Lung Non-Squamous Non-Small Cell Carcinoma1 trial

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02193282·390 enrolled

Recurrent Lung Non-Small Cell Carcinoma1 trial

A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib Plus Cabozantinib as 2nd or 3rd Line Therapy in Patients With EGFR Wild-Type NSCLC

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT01708954·125 enrolled

Cirrhosis, Liver1 trial

Phase II Clinical Trial of Low-dose Erlotinib for Hepatocellular Carcinoma Chemoprevention

Not yet recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT04172779·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for erlotinib hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for erlotinib hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Texas Southwestern Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: UUniversity of Texas Southwestern Medical Center

erlotinib hydrochloride

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2030

Trials by Indication[1]

Lung Non-Squamous Non-Small Cell Carcinoma1 trial

Recurrent Lung Non-Small Cell Carcinoma1 trial

Cirrhosis, Liver1 trial

References

Drug Info

Quick Facts

Related News